Economic consequences of molecular profiling for metastatic solid tumors. Cost-effectiveness of pazopanib (PAZ) versus sunitinib (SUN) as first-line treatment of metastatic renal cell carcinoma (mRCC) ...
Time-driven activity-based costing and the impact on cost measurement in the face of health reform. A rapid method to estimate the value of genetic analysis of excised cancers: A comparison in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results